PATENT CLAIM ANALYSIS

Application Number: 16365459
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "001000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Claim (Index 28):
The method of  claim 1 , wherein the human being has suffered from the CRPS for about 6 years to about 10 years on the first day that the neridronic acid is administered to the human being.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 99.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15820305', '15782480', '15703891', '15814745', '15710759']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7644339705803902
- 35 USC 102 Novelty (BERT): 0.5595684520671247
- Combined Prediction Score: 0.7439474187290637
- Mean Citation Score: 299.617522
- Max Citation Score: 314.9670700000001
- Similarity Product: 221.30179652900463

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test